CoChat

Accuracy of cytokeratin 18 (M30 and M65) in detecting non-alcoholic steatohepatitis and fibrosis: A systematic review and meta-analysis

Open access

The DOI matches its Crossref record; 66 of the 66 references it cites were found in a registry or an index.

Abstract

INTRODUCTION: Association between elevated cytokeratin 18 (CK-18) levels and hepatocyte death has made circulating CK-18 a candidate biomarker to differentiate non-alcoholic fatty liver from non-alcoholic steatohepatitis (NASH). Yet studies produced variable diagnostic performance. We aimed to provide summary estimates with increased precision for the accuracy of CK-18 (M30, M65) in detecting NASH and fibrosis among non-alcoholic fatty liver disease (NAFLD) adults. METHODS: We searched five databases to retrieve studies evaluating CK-18 against a liver biopsy in NAFLD adults. Reference screening, data extraction and quality assessment (QUADAS-2) were independently conducted by two authors. Meta-analyses were performed for five groups based on the CK-18 antigens and target conditions, using one of two methods: linear mixed-effects multiple thresholds model or bivariate logit-normal random-effects model. RESULTS: We included 41 studies, with data on 5,815 participants. A wide range of disease prevalence was observed. No study reported a pre-defined cut-off. Thirty of 41 studies provided sufficient data for inclusion in any of the meta-analyses. Summary AUC [95% CI] were: 0.75 [0.69-0.82] (M30) and 0.82 [0.69-0.91] (M65) for NASH; 0.73 [0.57-0.85] (M30) for fibrotic NASH; 0.68 (M30) for significant (F2-4) fibrosis; and 0.75 (M30) for advanced (F3-4) fibrosis. Thirteen studies used CK-18 as a component of a multimarker model. CONCLUSIONS: For M30 we found lower diagnostic accuracy to detect NASH compared to previous meta-analyses, indicating a limited ability to act as a stand-alone test, with better performance for M65. Additional external validation studies are needed to obtain credible estimates of the diagnostic accuracy of multimarker models.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1371/journal.pone.0238717

Cites

66 of 66 references verified0 citation errors · 0 not checkable

Statistics

Figures

Fig 1 PRISMA flow diagram of included primary studies.
Fig 1 PRISMA flow diagram of included primary studies.CC BY · PubMed Central
Fig 2 Multiple threshold SROC and ROC curves for detecting NASH. Multiple threshold SROC and ROC curves for CK-18 M30 (A-B) and M65 (C-D) in detecting NASH. Each point represents a reported threshold value, points of the same color represent thresholds reported within the same study. The x-axis indicates 1 –specificity, and the y-axis, sensitivity. The cross in the SROC curve indicates the Youden-based threshold value: A. Youden-threshold: 304 U/L, sensitivity: 0.61 (95% CI: 0.51–0.71), specificity: 0.81 (95% CI: 0.71–0.88), AUC: 0.75 (95% CI: 0.69–0.82) for CK-18 M30. C. Youden-threshold: 478 U/L, sensitivity: 0.75 (95% CI: 0.51–0.90), specificity: 0.76 (95% CI: 0.49–0.91), AUC: 0.82 (95% CI: 0.69–0.91) for CK-18 M65.
Fig 2 Multiple threshold SROC and ROC curves for detecting NASH. Multiple threshold SROC and ROC curves for CK-18 M30 (A-B) and M65 (C-D) in detecting NASH. Each point represents a reported threshold value, points of the same color represent thresholds reported within the same study. The x-axis indicates 1 –specificity, and the y-axis, sensitivity. The cross in the SROC curve indicates the Youden-based threshold value: A. Youden-threshold: 304 U/L, sensitivity: 0.61 (95% CI: 0.51–0.71), specificity: 0.81 (95% CI: 0.71–0.88), AUC: 0.75 (95% CI: 0.69–0.82) for CK-18 M30. C. Youden-threshold: 478 U/L, sensitivity: 0.75 (95% CI: 0.51–0.90), specificity: 0.76 (95% CI: 0.49–0.91), AUC: 0.82 (95% CI: 0.69–0.91) for CK-18 M65.CC BY · PubMed Central
Fig 3 Positive and negative predictive values and thresholds for detecting NASH. Plots illustrating the negative and positive predictive values of M30 (A-B) and M65 (C-D) in detecting NASH at corresponding threshold values, projected by the multiple thresholds model. Each colored line represents a different prevalence setting, ranging from 5% to 70%. The y-axis indicates the predictive value and the x-axis indicated the threshold values for CK-18.
Fig 3 Positive and negative predictive values and thresholds for detecting NASH. Plots illustrating the negative and positive predictive values of M30 (A-B) and M65 (C-D) in detecting NASH at corresponding threshold values, projected by the multiple thresholds model. Each colored line represents a different prevalence setting, ranging from 5% to 70%. The y-axis indicates the predictive value and the x-axis indicated the threshold values for CK-18.CC BY · PubMed Central

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 66 references

Cited by

See all 74

Metadata

Authors
Lee, J., Vali, Y., Boursier, J., Duffin, K., Verheij, J., Brosnan, M. J., Zwinderman, K., Anstee, Q. M., Bossuyt, P. M., & Zafarmand, M. H.
Affiliations
  • Amsterdam University Medical Centers (NL)
  • Centre Hospitalier Universitaire d'Angers (FR)
  • Eli Lilly (United States) (US)
  • Pfizer (United States) (US)
  • Newcastle upon Tyne Hospitals NHS Foundation Trust (GB)
Corresponding author
Lee, Jenny
Venue
PLOS ONE
Published
2020-09-11
Volume
15
Issue
9
Pages
e0238717
ISSN
1932-6203 (ISSN-L)
OpenAlex
W3084487116
Cited by
74
References
66
Citations by year
2026: 5 · 2025: 11 · 2024: 15 · 2023: 20 · 2022: 12 · 2021: 11
FWCI
1.57
Type
journal article
Language
en
Open access
Locations
  • PLoS ONE (publishedVersion, cc-by)
  • PubMed Central (publishedVersion, cc-by)
  • PubMed (publishedVersion)
  • Data Archiving and Networked Services (DANS) (submittedVersion, other-oa)
  • HAL (submittedVersion)
  • RePEc: Research Papers in Economics (submittedVersion)
  • DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
  • Pure Amsterdam UMC (submittedVersion, cc-by)
  • Newcastle University ePrints (Newcastle Univesity) (cc-by)
Funders
Innovative Medicines Initiative (777377)
Topics
  • Health Sciences › Medicine › Hepatology › Liver Disease Diagnosis and Treatment
  • Health Sciences › Medicine › Hepatology › Liver Diseases and Immunity
  • Health Sciences › Medicine › Pathology and Forensic Medicine › Alcohol Consumption and Health Effects
Keywords
cytokeratin 18, M30, M65, nonalcoholic steatohepatitis, liver fibrosis, non-alcoholic fatty liver disease, circulating biomarkers, diagnostic accuracy, hepatocyte death, liver biopsy
MeSH terms
Adult, Biopsy, Female, Humans, Liver, Liver Cirrhosis, Male, Middle Aged, Peptide Fragments, Biomarkers, Cell Death, Hepatocytes, Keratin-18, Non-alcoholic Fatty Liver Disease

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Accuracy of cytokeratin 18 (M30 and M65) in detecting non-alcoholic steatohepatitis and fibrosis: A systematic review and meta-analysis. https://app.cochat.ai/papers/10.1371/journal.pone.0238717
The paper
Lee, J., Vali, Y., Boursier, J., Duffin, K., Verheij, J., Brosnan, M. J., Zwinderman, K., Anstee, Q. M., Bossuyt, P. M., & Zafarmand, M. H. (2020). Accuracy of cytokeratin 18 (M30 and M65) in detecting non-alcoholic steatohepatitis and fibrosis: A systematic review and meta-analysis. PLOS ONE. https://doi.org/10.1371/journal.pone.0238717

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.